MaxCyte, Inc (MXCT) Operating Margin

Public company logo of MaxCyte (MXCT)

MaxCyte, Inc. (MXCT) equipment production is concentrated in the US and is critically important for pharma giants. The operating margin trend on this precise GURU.Markets chart shows that the current level is around -79.00. Business stability relies on SPL licensing of the Flow Electroporation platform, while dependency risks are minimized through internal control of software and patents despite outsourcing hardware.

MaxCyte Inc. (MXCT): Operating Profitability from 07/04/2022 to 11/19/2026

Metric breakdowns and analytics for maxcyte.com (MXCT)

- share price and consensus valuation forecast:
Analysis of all company metrics:MaxCyte Inc.
Finished products of MaxCyte, Inc.

For MaxCyte, Inc. (MXCT), the operating margin reflects the monetization efficiency of its electroporation system and recurring payments for consumables. This indicator measures the profit share from core operations, stripped of the impact of debt service and tax obligations. The calculation is based on dividing operating income by total sales volume. Growth in this metric confirms the scalability of the royalty model, while positive momentum indicates a high margin of safety for the business.